Hypogammaglobulinemia: Difference between revisions
Line 34: | Line 34: | ||
* Between 1950-1965, primary [[immunodeficiencies]] affecting all major levels of [[immune system]] were first described.<ref name="pmid8433870">{{cite journal |vauthors=Stiehm ER |title=New and old immunodeficiencies |journal=Pediatr. Res. |volume=33 |issue=1 Suppl |pages=S2–7; discussion S7–8 |date=January 1993 |pmid=8433870 |doi=10.1203/00006450-199305001-00007 |url=}}</ref> | * Between 1950-1965, primary [[immunodeficiencies]] affecting all major levels of [[immune system]] were first described.<ref name="pmid8433870">{{cite journal |vauthors=Stiehm ER |title=New and old immunodeficiencies |journal=Pediatr. Res. |volume=33 |issue=1 Suppl |pages=S2–7; discussion S7–8 |date=January 1993 |pmid=8433870 |doi=10.1203/00006450-199305001-00007 |url=}}</ref> | ||
* Use of immunoglobulins for the | * Use of [[immunoglobulins]] for the treatmen<nowiki/>t of [[hypogammaglobulinemia]] was practised as early as 1950's.<ref name="pmid13357304">{{cite journal |vauthors= |title=USE OF immune globulins for the treatment of agammaglobulinemia or hypogammaglobulinemia |journal=J Am Med Assoc |volume=162 |issue=2 |pages=117 |date=September 1956 |pmid=13357304 |doi= |url=}}</ref> | ||
* [[Therapeutic]] results in the use of human serum [[gamma globulins]] have been published during the late 1950's. <ref name="pmid13623695">{{cite journal |vauthors=SOULIER JP, BADILLET M, HERZOG F |title=[Therapeutic results in the use of human serum gamma globulins; survey of 6, 602 cases. I. Main indications for their use in infections diseases] |language=French |journal=Presse Med |volume=66 |issue=84 |pages=1881–4 |date=November 1958 |pmid=13623695 |doi= |url=}}</ref><ref name="pmid13591696">{{cite journal |vauthors=OLIVE BADOSA A |title=[Gamma globulin in immunological therapeutics: critical analysis] |language=Spanish; Castilian |journal=Rev Clin Esp |volume=69 |issue=6 |pages=361–4 |date=June 1958 |pmid=13591696 |doi= |url=}}</ref> | * [[Therapeutic]] results in the use of human serum [[gamma globulins]] have been published during the late 1950's. <ref name="pmid13623695">{{cite journal |vauthors=SOULIER JP, BADILLET M, HERZOG F |title=[Therapeutic results in the use of human serum gamma globulins; survey of 6, 602 cases. I. Main indications for their use in infections diseases] |language=French |journal=Presse Med |volume=66 |issue=84 |pages=1881–4 |date=November 1958 |pmid=13623695 |doi= |url=}}</ref><ref name="pmid13591696">{{cite journal |vauthors=OLIVE BADOSA A |title=[Gamma globulin in immunological therapeutics: critical analysis] |language=Spanish; Castilian |journal=Rev Clin Esp |volume=69 |issue=6 |pages=361–4 |date=June 1958 |pmid=13591696 |doi= |url=}}</ref> | ||
* [[Treatment Guidelines from The Medical Letter|Treatmen]]<nowiki/>t of various [[infectious]] [[diseases]] with the use of [[gamma globulins]] started during the late 1950's. [[Whooping cough]] was treated with [[placental]] [[immunoglobulin]] during the year 1959.<ref name="pmid13645155">{{cite journal |vauthors=LODODO KS, BAVAEVA SN |title=[Treatment of whooping cough with placental gamma-globulin] |language=Russian |journal=Pediatriia |volume=14 |issue=2 |pages=38–42 |date=February 1959 |pmid=13645155 |doi= |url=}}</ref><ref name="pmid13648484">{{cite journal |vauthors=SAXL O |title=[Treatment of severe infections with gamma globulin] |language=German |journal=Z Arztl Fortbild (Jena) |volume=52 |issue=24 |pages=1030–3 |date=December 1958 |pmid=13648484 |doi= |url=}}</ref> | * [[Treatment Guidelines from The Medical Letter|Treatmen]]<nowiki/>t of various [[infectious]] [[diseases]] with the use of [[gamma globulins]] started during the late 1950's. [[Whooping cough]] was treated with [[placental]] [[immunoglobulin]] during the year 1959.<ref name="pmid13645155">{{cite journal |vauthors=LODODO KS, BAVAEVA SN |title=[Treatment of whooping cough with placental gamma-globulin] |language=Russian |journal=Pediatriia |volume=14 |issue=2 |pages=38–42 |date=February 1959 |pmid=13645155 |doi= |url=}}</ref><ref name="pmid13648484">{{cite journal |vauthors=SAXL O |title=[Treatment of severe infections with gamma globulin] |language=German |journal=Z Arztl Fortbild (Jena) |volume=52 |issue=24 |pages=1030–3 |date=December 1958 |pmid=13648484 |doi= |url=}}</ref> |
Revision as of 18:38, 6 August 2018
Hypogammaglobulinemia | |
ICD-10 | D80.0-D80.1 |
---|---|
ICD-9 | 279.00 |
DiseasesDB | 6426 |
MedlinePlus | 001307 |
eMedicine | med/1120 ped/54 |
MeSH | D000361 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vindhya BellamKonda, M.B.B.S [2]
Synonyms and keywords:
Overview
Hypogammaglobulinemia is a type of primary immune deficiency disease.[1]
Hypogammaglobulinemia is a characteristic of common variable immunodeficiency.[2] "Hypogammaglobulinemia" is largely synonymous with "agammaglobulinemia". When the latter term is used (as in "X-linked agammaglobulinemia") it implies that gamma globulins are not merely reduced, but completely absent. Modern assays have allowed most agammaglobulinemias to be more precisely defined as hypogammaglobulinemias,[3] but the distinction is not usually clinically relevant.
"Hypogammaglobulinemia" is distinguished from dysgammaglobulinemia, which is a reduction in some types of gamma globulins, but not others.[4]
Historical Perspective
- Dr. Robert A Good and March of dimes foundation maintained a close association for a quarter century in the fight against immunodeficiency diseases.[5]
- Immunodeficiency diseases such as ataxia telangiectasia have been described as early as 1920's, wiskott aldrich's during 1930's.
- Between 1950-1965, primary immunodeficiencies affecting all major levels of immune system were first described.[6]
- Use of immunoglobulins for the treatment of hypogammaglobulinemia was practised as early as 1950's.[7]
- Therapeutic results in the use of human serum gamma globulins have been published during the late 1950's. [8][9]
- Treatment of various infectious diseases with the use of gamma globulins started during the late 1950's. Whooping cough was treated with placental immunoglobulin during the year 1959.[10][11]
Classification
Type | OMIM | Gene |
---|---|---|
AGM1 | 601495 | IGHM |
AGM2 | 613500 | IGLL1 |
AGM3 | 613501 | CD79A |
AGM4 | 613502 | BLNK |
AGM5 | 613506 | LRRC8A |
AGM6 | 612692 | CD79B |
Pathophysiology
The exact pathogenesis of [disease name] is not fully understood.
OR
It is thought that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].
OR
[Pathogen name] is usually transmitted via the [transmission route] route to the human host.
OR
Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell.
OR
[Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells].
OR
The progression to [disease name] usually involves the [molecular pathway].
OR
The pathophysiology of [disease/malignancy] depends on the histological subtype.
Causes
Hypogammaglobulinemia is caused by:
Differentiating Hypogammaglobulinemia from Other Diseases
Hypogammaglobulinemia must be differentiated from Bronchiectasis, complement deficiencies, and cystic fibrosis
Medical condition | Characteristic features |
---|---|
Complement deficiencies |
|
Bronchiectasis |
|
Cystic fibrosis |
|
Staphylococcal associated glomerulonephritis |
|
Epidemiology and Demographics
The incidence/prevalence of [disease name] is approximately [number range] per 100,000 individuals worldwide.
OR
In [year], the incidence/prevalence of [disease name] was estimated to be [number range] cases per 100,000 individuals worldwide.
OR
In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate of [number range]%.
Patients of all age groups may develop [disease name].
OR
The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
OR
[Disease name] commonly affects individuals younger than/older than [number of years] years of age.
OR
[Chronic disease name] is usually first diagnosed among [age group].
OR
[Acute disease name] commonly affects [age group].
There is no racial predilection to [disease name].
OR
[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
[Disease name] affects men and women equally.
OR
[Gender 1] are more commonly affected by [disease name] than [gender 2]. The [gender 1] to [gender 2] ratio is approximately [number > 1] to 1.
The majority of [disease name] cases are reported in [geographical region].
OR
[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
Risk Factors
Common risk factors in the development of hypogammaglobulinemia include:
- Family history of a primary immune deficiency disorder
- Medical therapy with drugs such as
- Bruton's agammaglobulinemia[13]
Screening
There is insufficient evidence to recommend routine screening for [disease/malignancy].
OR
According to the [guideline name], screening for [disease name] is not recommended.
OR
According to the [guideline name], screening for [disease name] by [test 1] is recommended every [duration] among patients with [condition 1], [condition 2], and [condition 3].
Natural History, Complications, and Prognosis
Common complications of hypogammaglobulinemia include:
- Recurrent infections
- Growth retardation( in children)
- Autoimmune disorders
- Increased risk of cancer
- Death due to serious infections
Diagnosis
Diagnostic Study of Choice
The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met: [criterion 1], [criterion 2], [criterion 3], and [criterion 4].
OR
The diagnosis of [disease name] is based on the [criteria name] criteria, which include [criterion 1], [criterion 2], and [criterion 3].
OR
The diagnosis of [disease name] is based on the [definition name] definition, which includes [criterion 1], [criterion 2], and [criterion 3].
OR
There are no established criteria for the diagnosis of [disease name].
History and Symptoms
The majority of patients with [disease name] are asymptomatic.
OR
The hallmark of [disease name] is [finding]. A positive history of [finding 1] and [finding 2] is suggestive of [disease name]. The most common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3]. Common symptoms of [disease] include [symptom 1], [symptom 2], and [symptom 3]. Less common symptoms of [disease name] include [symptom 1], [symptom 2], and [symptom 3].
Physical Examination
Common physical examination findings of hypogammaglobulinemia include :
- Growth retardation
- Paucity of tonsillar tissue
- Skin: rash, livedo reticularis
- Splenomegaly or hypersplenism in patients with common variable immunodeficiency.
- Pulmonary: Rales, rhonchi and wheezing
- Cardiovascular examination: Chronic respiratory insufficiency can result in pulmonary hypertension and right heart failure.
- Extremities: Digital clubbing
Laboratory Findings
An elevated/reduced concentration of serum/blood/urinary/CSF/other [lab test] is diagnostic of [disease name].
OR
Laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
OR
[Test] is usually normal among patients with [disease name].
OR
Some patients with [disease name] may have elevated/reduced concentration of [test], which is usually suggestive of [progression/complication].
OR
There are no diagnostic laboratory findings associated with [disease name].
Electrocardiogram
There are no ECG findings associated with hypogammaglobulinemia.
X-ray
There are no x-ray findings associated with [disease name].
OR
An x-ray may be helpful in the diagnosis of [disease name]. Findings on an x-ray suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].
OR
There are no x-ray findings associated with [disease name]. However, an x-ray may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].
Echocardiography or Ultrasound
There are no echocardiography/ultrasound findings associated with [disease name].
OR
Echocardiography/ultrasound may be helpful in the diagnosis of [disease name]. Findings on an echocardiography/ultrasound suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].
OR
There are no echocardiography/ultrasound findings associated with [disease name]. However, an echocardiography/ultrasound may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].
CT scan
There are no CT scan findings associated with [disease name].
OR
[Location] CT scan may be helpful in the diagnosis of [disease name]. Findings on CT scan suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].
OR
There are no CT scan findings associated with [disease name]. However, a CT scan may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].
MRI
There are no MRI findings associated with [disease name].
OR
[Location] MRI may be helpful in the diagnosis of [disease name]. Findings on MRI suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].
OR
There are no MRI findings associated with [disease name]. However, a MRI may be helpful in the diagnosis of complications of [disease name], which include [complication 1], [complication 2], and [complication 3].
Other Imaging Findings
There are no other imaging findings associated with [disease name].
OR
[Imaging modality] may be helpful in the diagnosis of [disease name]. Findings on an [imaging modality] suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].
Other Diagnostic Studies
There are no other diagnostic studies associated with [disease name].
OR
[Diagnostic study] may be helpful in the diagnosis of [disease name]. Findings suggestive of/diagnostic of [disease name] include [finding 1], [finding 2], and [finding 3].
OR
Other diagnostic studies for [disease name] include [diagnostic study 1], which demonstrates [finding 1], [finding 2], and [finding 3], and [diagnostic study 2], which demonstrates [finding 1], [finding 2], and [finding 3].
Treatment
Medical Therapy
There is no treatment for [disease name]; the mainstay of therapy is supportive care.
OR
Supportive therapy for [disease name] includes [therapy 1], [therapy 2], and [therapy 3].
OR
The majority of cases of [disease name] are self-limited and require only supportive care.
OR
[Disease name] is a medical emergency and requires prompt treatment.
OR
The mainstay of treatment for [disease name] is [therapy].
OR The optimal therapy for [malignancy name] depends on the stage at diagnosis.
OR
[Therapy] is recommended among all patients who develop [disease name].
OR
Pharmacologic medical therapy is recommended among patients with [disease subclass 1], [disease subclass 2], and [disease subclass 3].
OR
Pharmacologic medical therapies for [disease name] include (either) [therapy 1], [therapy 2], and/or [therapy 3].
OR
Empiric therapy for [disease name] depends on [disease factor 1] and [disease factor 2].
OR
Patients with [disease subclass 1] are treated with [therapy 1], whereas patients with [disease subclass 2] are treated with [therapy 2].
Surgery
Surgical intervention is not recommended for the management of [disease name].
OR
Surgery is not the first-line treatment option for patients with [disease name]. Surgery is usually reserved for patients with either [indication 1], [indication 2], and [indication 3]
OR
The mainstay of treatment for [disease name] is medical therapy. Surgery is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].
OR
The feasibility of surgery depends on the stage of [malignancy] at diagnosis.
OR
Surgery is the mainstay of treatment for [disease or malignancy].
Primary Prevention
There are no established measures for the primary prevention of hypogammaglobulinemia
Secondary Prevention
There are no established measures for the secondary prevention of [disease name].
OR
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
References
- ↑ Template:DorlandsDict
- ↑ Template:DorlandsDict
- ↑ Template:DorlandsDict
- ↑ Template:DorlandsDict
- ↑ Rose DW (2007). "Robert A. Good, the March of Dimes, and immunodeficiency: an historical perspective". Immunol. Res. 38 (1–3): 51–4. PMID 17917009.
- ↑ Stiehm ER (January 1993). "New and old immunodeficiencies". Pediatr. Res. 33 (1 Suppl): S2–7, discussion S7–8. doi:10.1203/00006450-199305001-00007. PMID 8433870.
- ↑ "USE OF immune globulins for the treatment of agammaglobulinemia or hypogammaglobulinemia". J Am Med Assoc. 162 (2): 117. September 1956. PMID 13357304.
- ↑ SOULIER JP, BADILLET M, HERZOG F (November 1958). "[Therapeutic results in the use of human serum gamma globulins; survey of 6, 602 cases. I. Main indications for their use in infections diseases]". Presse Med (in French). 66 (84): 1881–4. PMID 13623695.
- ↑ OLIVE BADOSA A (June 1958). "[Gamma globulin in immunological therapeutics: critical analysis]". Rev Clin Esp (in Spanish; Castilian). 69 (6): 361–4. PMID 13591696.
- ↑ LODODO KS, BAVAEVA SN (February 1959). "[Treatment of whooping cough with placental gamma-globulin]". Pediatriia (in Russian). 14 (2): 38–42. PMID 13645155.
- ↑ SAXL O (December 1958). "[Treatment of severe infections with gamma globulin]". Z Arztl Fortbild (Jena) (in German). 52 (24): 1030–3. PMID 13648484.
- ↑ Christou E, Giardino G, Worth A, Ladomenou F (November 2017). "Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab". Int. Rev. Immunol. 36 (6): 352–359. doi:10.1080/08830185.2017.1346092. PMID 28800262. Vancouver style error: initials (help)
- ↑ Taneja A, Chhabra A. PMID 28846295. Missing or empty
|title=
(help)